A detailed history of Alliancebernstein L.P. transactions in Annexon, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 127,360 shares of ANNX stock, worth $657,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,360
Previous 146,450 13.04%
Holding current value
$657,177
Previous $717,000 5.02%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.49 - $7.2 $85,714 - $137,448
-19,090 Reduced 13.04%
127,360 $753,000
Q2 2024

Aug 14, 2024

BUY
$4.33 - $6.79 $458,243 - $718,585
105,830 Added 260.54%
146,450 $717,000
Q2 2023

Aug 15, 2023

BUY
$2.1 - $6.37 $85,302 - $258,749
40,620 New
40,620 $142,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $5.24 Million - $10.1 Million
-2,483,650 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$2.73 - $11.94 $1.07 Million - $4.7 Million
393,295 Added 18.81%
2,483,650 $6.78 Million
Q4 2021

Feb 14, 2022

BUY
$11.49 - $22.0 $4.29 Million - $8.21 Million
373,074 Added 21.72%
2,090,355 $24 Million
Q3 2021

Nov 10, 2021

BUY
$16.35 - $23.4 $1.96 Million - $2.8 Million
119,758 Added 7.5%
1,717,281 $32 Million
Q2 2021

Jul 30, 2021

BUY
$17.81 - $27.48 $2.68 Million - $4.13 Million
150,368 Added 10.39%
1,597,523 $36 Million
Q1 2021

May 06, 2021

BUY
$22.0 - $35.01 $6.86 Million - $10.9 Million
311,677 Added 27.45%
1,447,155 $40.3 Million
Q4 2020

Feb 08, 2021

BUY
$20.81 - $30.55 $3.25 Million - $4.77 Million
156,056 Added 15.93%
1,135,478 $28.4 Million
Q3 2020

Nov 12, 2020

BUY
$17.5 - $30.23 $17.1 Million - $29.6 Million
979,422 New
979,422 $29.6 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $246M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.